TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02358863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Docetaxel
Description: Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRI/EPI
Description: Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
Study: NCT04358705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Experimental Marketplace (ETM)
Description: Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aim 3 survey
Description: Consists of:~* A screener and demographic data collection.~* A tobacco product withdrawal scale~* Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~* The tobacco product withdrawal scale again~* Measurements of nicotine dependence and flavor preferences
Study: NCT04108104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: 3-month treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: 3-month treatment
Study: NCT04358705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aim 3 survey
Description: Consists of:~* A screener and demographic data collection.~* A tobacco product withdrawal scale~* Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~* The tobacco product withdrawal scale again~* Measurements of nicotine dependence and flavor preferences

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Interviews
Description: Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Aim 1 Interviews
Description: Participants from the preceding online survey (who identify as women from Aim 1/supplemental aim 1 survey) who agreed to be contacted for future study will be emailed an invitation to the eligibility screener. Individuals interested will complete a screener to ensure participants identify as women and to verify that they have ever used cigarillos. Eligible participants will be contacted to schedule a 60- to 90-minute Zoom interview about their tobacco, nicotine, and cannabis product use experiences, with particular focus on flavored cigarillo usage initiation, current use, and responses to potential flavor restrictions.
Study: NCT02868450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Sample
Study: NCT02358863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI/Docetaxel
Description: Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan/Docetaxel
Description: Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60-100 mg/m2 IV day 1 every 21 days
Study: NCT05877040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
Study: NCT00162461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin single dose (300 mg)
Study: NCT03620357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: CGM Group: Dexcom G6 CGM
Study: NCT04108104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyproheptadine
Description: 3-month treatment
Study: NCT03620357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: SMBG Group: Blood Glucose Meter
Study: NCT04579172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervico- isthmic compression suture
Description: Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior wall uterine resection:
Description: After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
Study: NCT03623360

Intervention type: DIAGNOSTIC_TEST
Intervention: Free breathing DCE-MRI
Description: Free breathing DCE-MRI
Study: NCT03721276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EQuIP (Empowering Queer Identities in Psychotherapy)
Description: Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EQuIP (Empowering Queer Identities in Psychotherapy)
Description: Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
Study: NCT04918264

Intervention type: DRUG
Intervention: Fluoropyrimidine treatment (5-FU or capecitabine) and dosage
Description: In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database

Intervention type: DRUG
Intervention: Fluoropyrimidine treatment (5-FU or capecitabine) and dosage
Description: In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
Study: NCT04312607

Intervention type: DIAGNOSTIC_TEST
Intervention: BCR-ABL gene PCR
Description: peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells

Intervention type: DIAGNOSTIC_TEST
Intervention: BCR-ABL gene PCR
Description: peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
Study: NCT02958306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
Study: NCT00369226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade)
Description: Infusion for a total of 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Taken until Doctor determines it is not necessary any more
Study: NCT04918264

Intervention type: OTHER
Intervention: Uracil dosage
Description: For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.

Intervention type: OTHER
Intervention: Uracil dosage
Description: For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.

Intervention type: BEHAVIORAL
Intervention: Overall survival
Description: For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil \<16 vs Uracil ≥16).

Intervention type: BEHAVIORAL
Intervention: Overall survival
Description: For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil \<16 vs Uracil ≥16).
Study: NCT00651573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion at hematocrit value less than 24%
Description: transfusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion at hematocrit value less than 28%
Description: transfusion
Study: NCT01316120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compare different self-obtained specimen for HPV identification
Description: Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compare different self-obtained specimen for HPV identification
Description: Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
Study: NCT02323477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: stem cell transplantation
Description: Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
Study: NCT03218007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: to evaluate expression and functionnaly activity of A2AR
Study: NCT01563003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This condition involves 16 weekly CBT sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
Study: NCT04173910

Intervention type: PROCEDURE
Intervention: Ultrasound LPEC/Sellick
Description: We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
Study: NCT01696396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrilumab
Description: Administered by subcutaneous injection.
Study: NCT01403714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Artery Stenting
Description: If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
Study: NCT00369226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Infusion for a total of 4 doses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood stem cell transplantation
Description: Allogeneic Non-myeloablative peripheral blood stem cell transplantation
Study: NCT03741023

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw (venipuncture or fingerstick)
Description: Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw (venipuncture or fingerstick)
Description: Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw (venipuncture or fingerstick)
Description: Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
Study: NCT02408354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin
Description: Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
Study: NCT03995056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity aerobic interval training
Description: The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices.
Study: NCT01829230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Day Acuvue Moist
Description: Lenses will be worn in a daily wear modality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Day Acuvue Moist
Description: Lenses will be worn in a daily wear modality
Study: NCT02857933

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
Study: NCT01696396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrilumab
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrilumab
Description: Administered by subcutaneous injection.
Study: NCT00031980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study: NCT00830713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Melanocyte-keratinocyte transplantation procedure (MKTP)
Description: skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
Study: NCT04372654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroducer Sleeve
Description: The device's safety will be assessed at the radial and femoral puncture site

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroducer Sleeve
Description: The device's safety will be assessed at the radial and femoral puncture site
Study: NCT02323841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
Study: NCT01430325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen (1.5 atm abs)
Description: Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen (1.5 atm abs)
Description: Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
Study: NCT01696396

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abrilumab
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to abrilumab administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to abrilumab administered by subcutaneous injection
Study: NCT02940353

Intervention type: DEVICE
Group type: OTHER
Intervention: TREFOIL concept
Study: NCT01393561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Brompheniramine + phenylephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 2
Description: Placebo
Study: NCT01430325

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Chamber Session
Description: Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
Study: NCT03362723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
Study: NCT02075047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oral capsules
Description: Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone oral capsules
Description: Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
Study: NCT03552536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8583
Description: A single oral dose of MK-8583 in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8583
Description: A single oral dose of MK-8583 in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8583
Description: A single oral dose of MK-8583 in capsule form
Study: NCT01759563

Intervention type: DEVICE
Group type: OTHER
Intervention: nasopharyngeal targeted brain cooling
Study: NCT01929720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for worry, uncertainty & insomnia
Description: This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy for worry, uncertainty & insomnia
Description: This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
Study: NCT02763475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60mg/kg by vein on day -6